SELLAS Loses GPS Arbitration, Ordered to Pay $1M; Cash at $138.3M
SLS has more than doubled off its 52-week low of $1.39.
Summary
SELLAS disclosed a preliminary cash balance of $138.3 million and an adverse arbitration ruling dismissing its claims against 3D Medicines, with $1 million in costs awarded to the counterparty.
Key Events · Legal and Risk Events · SLS
-
Arbitration Dismissed
The HKIAC arbitrator dismissed SELLAS's claims against 3D Medicines and ordered SELLAS to pay approximately $1.0 million in legal fees and costs.
-
Milestone Dispute Lost
The $13 million milestone payment that was the subject of the arbitration will not be paid now; 3D Medicines continues GPS development in Greater China under the existing license.
-
Remaining Milestone Potential
$191.5 million in potential future milestone payments remain under the license agreement as of March 31, 2026, though none are guaranteed.
-
Preliminary Cash Position
Unaudited cash and cash equivalents were estimated at $138.3 million as of June 30, 2026, up from $114.7 million pro forma at March 31, 2026, driven by warrant exercises.
Analysis · SLS · Life Sciences
The arbitration loss removes a potential near-term catalyst — the $13 million milestone dispute — and forces SELLAS to pay $1 million in costs. While the $191.5 million in remaining milestones stays intact, the dismissal signals that 3D Medicines retains control over GPS development in Greater China without immediate payment. The cash update of $138.3 million is solid but preliminary, and the arbitration outcome adds legal and financial uncertainty at a time when the pivotal Phase 3 REGAL trial is enrolling slower than expected.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLS was trading at $10.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $1.39 to $15.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.